Panobinostat is a hydroxamic acid formed by the formal condensation of the carboxy group of (2E)-3-[4-({[2-(2-methylindol-3-yl)ethyl]amino}methyl)phenyl]prop-2-enoic acid with the amino group of hydroxylamine. It is a histone deacetylase inhibitor used as its lactate salt in combination with bortezomib and dexamethasone for the treatment of multiple myeloma. It functions as an EC 3.5.1.98 inhibitor, an antineoplastic agent, and an angiogenesis modulating agent. It is a hydroxamic acid, a member of cinnamamides, a secondary amino compound, and a methylindole. It is the conjugate base of panobinostat(1+).
